Vizimpro (Dacomitinib) 45mg*30's | EGFR Inhibitor for NSCLC | GLT

Generic Information: Vizimpro (United States)

Vizimpro is the United States brand name of dacomitinib, a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed by Pfizer. The drug is supplied as film-coated tablets in 15 mg, 30 mg, and 45 mg strengths. This listing covers the 45 mg strength in a 30-tablet pack, the standard starting dose for adults. As an oral oncology medicine, dacomitinib is taken once daily, with or without food, which makes it practical for at-home treatment of EGFR-mutated lung cancer.

What Is Vizimpro Used For?

Vizimpro is prescribed as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors carry an EGFR exon 19 deletion or an exon 21 L858R substitution mutation, confirmed by an FDA-approved test. It is not a general lung-cancer drug — it only works for patients with these specific activating EGFR mutations, so genetic testing is the essential first step before treatment begins.

How Does Dacomitinib Work?

Dacomitinib binds irreversibly to the ATP pocket of EGFR, and unlike first-generation reversible inhibitors, it also covalently blocks HER2 and HER4. This covalent, pan-HER blockade keeps the downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling pathways switched off more durably, which slows the growth and spread of EGFR-driven cancer cells. In the ARCHER 1050 trial, this mechanism translated into a median progression-free survival of about 14.7 months, compared with 9.2 months for gefitinib.

Indications

Vizimpro is indicated specifically for the first-line treatment of metastatic NSCLC harboring EGFR exon 19 deletion or exon 21 L858R substitution mutations. Patients with these sensitizing mutations are the population that benefits; those without them should receive a different therapy. The medicine is not indicated for small-cell lung cancer or for EGFR wild-type tumors.

Dosage

The recommended dose is 45 mg taken orally once daily, at roughly the same time each day, and it may be taken with or without food. If a dose is missed, do not double up — simply take the next scheduled dose. Dose reductions to 30 mg or 15 mg may be applied to manage side effects such as diarrhea or skin reactions. Patients should avoid proton-pump inhibitors; if an antacid is needed, a locally-acting antacid or an H2-receptor antagonist taken at least 6 hours before or 10 hours after the dose is preferred.

Side Effects

The most common adverse reactions, occurring in more than 20% of patients, include diarrhea, rash, paronychia (nail-bed inflammation), stomatitis, decreased appetite, dry skin, weight loss, hair loss, cough, and itching. Diarrhea and skin reactions are usually manageable with supportive care and temporary dose adjustment. Serious but less common effects include interstitial lung disease (ILD) and embryo-fetal toxicity. Because ILD can be life-threatening, treatment must be stopped permanently if ILD is confirmed.

Storage

Store Vizimpro tablets at room temperature, below 30°C, in the original container, away from moisture and heat, and out of reach of children. There are no special refrigeration requirements, which simplifies handling for patients who need to keep the medicine at home.

Why Choose the GLT?

GLT supplies authentic, internationally sourced oncology medicines, and the United States version of Vizimpro is one of the options we can help source. Buyers outside the United States should be aware that the US list price of Vizimpro is among the highest in the world, so many international patients explore lower-cost sourcing routes for the same active ingredient. We focus on verified supply chains and clear documentation so that both institutional purchasers and individual patients understand exactly what they are ordering and where it comes from.

How to Order

To order dacomitinib through GLT, contact us directly on WhatsApp at +86 15234153837 or by email at [email protected]. Share the required strength, pack size, and your delivery country, and our team will confirm availability, sourcing origin, and shipping terms. We work with hospitals, pharmacies, and individual patients, and we are ready to provide the documentation required for import.

FAQ

Is Vizimpro available in the United States? Yes, Vizimpro is FDA-approved and available in the United States by prescription, but it is currently sold only as the brand-name product, with no US generic version yet available.

How much does Vizimpro cost in the US? In the United States, Vizimpro carries a very high list price, and a 30-day supply can be substantially more expensive than in several other markets. Actual out-of-pocket cost depends on insurance coverage and assistance programs.

Is dacomitinib the same as osimertinib? No. Both are EGFR inhibitors used in EGFR-mutated NSCLC, but dacomitinib is a second-generation, pan-HER inhibitor given as first-line therapy, whereas osimertinib is a third-generation inhibitor. They are different molecules with different dosing and safety profiles.